CN103298487B - Companion animals is treated - Google Patents
Companion animals is treated Download PDFInfo
- Publication number
- CN103298487B CN103298487B CN201180052915.1A CN201180052915A CN103298487B CN 103298487 B CN103298487 B CN 103298487B CN 201180052915 A CN201180052915 A CN 201180052915A CN 103298487 B CN103298487 B CN 103298487B
- Authority
- CN
- China
- Prior art keywords
- antibody
- cancer
- receptor
- companion animals
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001465754 Metazoa Species 0.000 title abstract description 82
- 201000011510 cancer Diseases 0.000 claims abstract description 125
- 102000004965 antibodies Human genes 0.000 claims description 186
- 108090001123 antibodies Proteins 0.000 claims description 186
- 239000000427 antigen Substances 0.000 claims description 85
- 102000038129 antigens Human genes 0.000 claims description 84
- 108091007172 antigens Proteins 0.000 claims description 84
- 241000282472 Canis lupus familiaris Species 0.000 claims description 58
- 239000003814 drug Substances 0.000 claims description 18
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 9
- 208000006971 Mastocytoma Diseases 0.000 claims description 7
- 210000000987 Immune System Anatomy 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 abstract description 7
- 108020003175 receptors Proteins 0.000 description 73
- 102000005962 receptors Human genes 0.000 description 73
- 230000004044 response Effects 0.000 description 56
- 230000036039 immunity Effects 0.000 description 43
- 210000004027 cells Anatomy 0.000 description 37
- 239000000203 mixture Substances 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 32
- 230000002163 immunogen Effects 0.000 description 31
- 241000282326 Felis catus Species 0.000 description 26
- 230000000240 adjuvant Effects 0.000 description 25
- 239000002671 adjuvant Substances 0.000 description 25
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 238000001802 infusion Methods 0.000 description 20
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 210000001519 tissues Anatomy 0.000 description 19
- 231100000915 pathological change Toxicity 0.000 description 16
- 230000036285 pathological change Effects 0.000 description 16
- 229960005486 vaccines Drugs 0.000 description 16
- 239000007924 injection Substances 0.000 description 15
- 102000004854 Immunoglobulin M Human genes 0.000 description 14
- 230000035693 Fab Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004851 Immunoglobulin G Human genes 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 230000001404 mediated Effects 0.000 description 11
- 239000000969 carrier Substances 0.000 description 10
- 239000004334 sorbic acid Substances 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 9
- 206010025323 Lymphomas Diseases 0.000 description 9
- 206010025310 Other lymphomas Diseases 0.000 description 9
- 241000283898 Ovis Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 210000003630 Histaminocyte Anatomy 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 201000008275 breast carcinoma Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108010045030 monoclonal antibodies Proteins 0.000 description 7
- 102000005614 monoclonal antibodies Human genes 0.000 description 7
- 201000008968 osteosarcoma Diseases 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000003442 weekly Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 208000001258 Hemangiosarcoma Diseases 0.000 description 6
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 6
- 210000001331 Nose Anatomy 0.000 description 6
- 210000000496 Pancreas Anatomy 0.000 description 6
- 210000002966 Serum Anatomy 0.000 description 6
- 201000003076 angiosarcoma Diseases 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 201000009030 carcinoma Diseases 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 210000000988 Bone and Bones Anatomy 0.000 description 5
- 210000000981 Epithelium Anatomy 0.000 description 5
- 210000000088 Lip Anatomy 0.000 description 5
- 210000004698 Lymphocytes Anatomy 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 210000000056 organs Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000001855 preneoplastic Effects 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 102100001249 ALB Human genes 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 4
- 206010059512 Apoptosis Diseases 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 210000001124 Body Fluids Anatomy 0.000 description 4
- 206010025650 Malignant melanoma Diseases 0.000 description 4
- 206010027476 Metastasis Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 229940050528 albumin Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- -1 antimicrobial Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000973 chemotherapeutic Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 201000008808 fibrosarcoma Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 3
- 230000036499 Half live Effects 0.000 description 3
- 102000018358 Immunoglobulins Human genes 0.000 description 3
- 108060003951 Immunoglobulins Proteins 0.000 description 3
- 229940102223 Injectable Solution Drugs 0.000 description 3
- 210000001616 Monocytes Anatomy 0.000 description 3
- 206010048810 Sebaceous hyperplasia Diseases 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 108091006028 chimera Proteins 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000000284 histiocytoma Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000003902 lesions Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 201000005218 sebaceous adenoma Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 206010008943 Chronic leukaemia Diseases 0.000 description 2
- 230000035700 Clearance Rate Effects 0.000 description 2
- 210000000172 Cytosol Anatomy 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 210000002615 Epidermis Anatomy 0.000 description 2
- 210000003743 Erythrocytes Anatomy 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 210000003714 Granulocytes Anatomy 0.000 description 2
- 210000003780 Hair Follicle Anatomy 0.000 description 2
- 210000002216 Heart Anatomy 0.000 description 2
- 210000002758 Humerus Anatomy 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 206010025482 Malaise Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 102000000033 Purinergic Receptors Human genes 0.000 description 2
- 108010080192 Purinergic Receptors Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 210000004761 Scalp Anatomy 0.000 description 2
- 210000002356 Skeleton Anatomy 0.000 description 2
- 235000018259 Solanum vestissimum Nutrition 0.000 description 2
- 240000002825 Solanum vestissimum Species 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- 239000003819 Toceranib Substances 0.000 description 2
- 206010044412 Transitional cell carcinoma Diseases 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000003187 abdominal Effects 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 230000000996 additive Effects 0.000 description 2
- 229960005467 algeldrate Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000845 anti-microbial Effects 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012523 bacterial endotoxin Substances 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 231100000406 dermatitis Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000001804 emulsifying Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 230000002147 killing Effects 0.000 description 2
- 230000002934 lysing Effects 0.000 description 2
- 101710031899 moon Proteins 0.000 description 2
- 230000000683 nonmetastatic Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002085 persistent Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 238000010194 physical measurement Methods 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001932 seasonal Effects 0.000 description 2
- 230000000405 serological Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 230000002522 swelling Effects 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000000015 thermotherapy Methods 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 101700023105 3L21 Proteins 0.000 description 1
- 101700012833 3S11 Proteins 0.000 description 1
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 description 1
- AOORBROPMMRREB-HBPAQXCTSA-N 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 AOORBROPMMRREB-HBPAQXCTSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 208000004064 Acoustic Neuroma Diseases 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K Aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024606 Amino Acids Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 208000006063 Angiosarcoma of the breast Diseases 0.000 description 1
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008154 B cell receptors Proteins 0.000 description 1
- 108060007869 BAH1 Proteins 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 206010004173 Basophilia Diseases 0.000 description 1
- 210000000013 Bile Ducts Anatomy 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005177 Blindness cortical Diseases 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010072813 Breast angiosarcoma Diseases 0.000 description 1
- 101700075228 CAT3 Proteins 0.000 description 1
- 208000002458 Carcinoid Tumor Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 101700015466 Cat-1 Proteins 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 210000000078 Claw Anatomy 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 208000009153 Cortical Blindness Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100019937 DHRS2 Human genes 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N Deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101700086161 GCH1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- WDZVNNYQBQRJRX-UHFFFAOYSA-K Gold(III) hydroxide Chemical compound O[Au](O)O WDZVNNYQBQRJRX-UHFFFAOYSA-K 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 229940000351 Hemocyte Drugs 0.000 description 1
- 210000003677 Hemocytes Anatomy 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 208000006572 Human Influenza Diseases 0.000 description 1
- 208000000069 Hyperpigmentation Diseases 0.000 description 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- 210000004731 Jugular Veins Anatomy 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 125000000631 L-cysteino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])S[H] 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 206010024627 Liposarcoma Diseases 0.000 description 1
- 210000003141 Lower Extremity Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 206010025538 Malignant ascite Diseases 0.000 description 1
- 210000004373 Mandible Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027191 Meningioma Diseases 0.000 description 1
- 210000000713 Mesentery Anatomy 0.000 description 1
- 206010061289 Metastatic neoplasm Diseases 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 229940052778 Neisseria meningitidis Drugs 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 229920001850 Nucleic acid sequence Polymers 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 210000004681 Ovum Anatomy 0.000 description 1
- 229940090244 Palladia Drugs 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229950008882 Polysorbate Drugs 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039667 Schwannoma Diseases 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 101710012187 TH Proteins 0.000 description 1
- 101700057439 TOXA Proteins 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001364 Upper Extremity Anatomy 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 210000001215 Vagina Anatomy 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 108010092132 anti-IgM Proteins 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 201000006230 breast fibrosarcoma Diseases 0.000 description 1
- 201000002858 breast osteosarcoma Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2S)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 101700021616 catA1 Proteins 0.000 description 1
- 101700065547 catA2 Proteins 0.000 description 1
- 210000003850 cellular structures Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 101700041767 ctxA Proteins 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229910021505 gold(III) hydroxide Inorganic materials 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000000004 hemodynamic Effects 0.000 description 1
- 230000002607 hemopoietic Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 231100001006 hyperpigmentation Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 101700023298 katG Proteins 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001394 metastastic Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 229940035032 monophosphoryl lipid A Drugs 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005161 thyroid carcinoma Diseases 0.000 description 1
- 229960005432 toceranib phosphate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Abstract
The present invention relates to use P2X7In immunotherapy makes companion animals body, cancer progression realizes minimizing.
Description
Invention field
The present invention relates to veterinary oncology, including the treatment of cancer in companion animals body.
Background of invention
Any prior art is mentioned by this specification and is not and is not to be construed as recognizing or implying in any form
This prior art is formed at Australia or the part of any other jurisdictional common knowledge or can reasonably expect that
This prior art confirms by those skilled in the art, understand and be considered as being correlated with.
Cancer sickness rate in companion animals (such as Canis familiaris L. and cat and other similar animals) is being continuously increased, and mesh
Before think that cancer is the dead first cause of senior animal.It is believed that in Canis familiaris L. body the sickness rate of annual cancer is about 2% to arrive
2.5% (about the same with the mankind) and cat is 1.5% to 2%.
In Canis familiaris L. body, there is the cancer of high incidence in the following order: lymphoma (about 20%);Mastocytoma is (about
18%);Soft tissue sarcoma (about 10%);Angiosarcoma (about 10%);Osteosarcoma (about 9%).Remainder typically comprises squama
Shape cell carcinoma, breast carcinoma, melanoma, histiocytoma and fibrosarcoma.
In cat body, there is the cancer of high incidence in the following order: lymphoma (about 25%);Mastocytoma (accounts for
The 22% of cutaneous tumor);Squamous cell carcinoma (more than the 11% of cutaneous tumor);Breast carcinoma (about 10%);And remaining part bag
Include angiosarcoma, osteosarcoma, fibrosarcoma, sebaceous hyperplasia/adenoma.
In veterinary oncology, the method for the treatment of of cancer includes surgical operation, radiotherapy, thermotherapy, photodynamic therapy and change
Treat.Gene therapy and immunotherapy are not also widely used.
Except Palladia (toceranib phosphate;Pfizer (Pfizer)), also there is no that other drug one is several can be executed
With listing license, as chemotherapeutics, the treatment of cancer in companion animals.This be primarily due to obtain listing license have
The high cost of association.
In most of jurisdictions, veterinary's oncologist has " label is outer " drug use privilege.The outer medicine of label makes
Can freely use the medicine being approved for a species (including the mankind) for another with referring to veterinary's oncologist
Species.Having had these privileges, occurred a kind of convention in veterinary oncology, thus oncologists tend to select those
The treatment of cancer in companion animals of the chemotherapeutics of significant clinical experience has been obtained in human tumor.
The example of the chemotherapeutics used in veterinary oncology at present and relevant indication illustrate in Table 1.
Table 1
A lot of problem and restriction is had for these chemotherapeutics.Such as, as observed in human treatment, these are changed
Compound and nonspecific action antagonism includes that the relevant toxicity of the somatoblast of bone marrow, GI epithelium and hair follicle is correlated with.Secondary
Effect includes immunosuppressant, anemia, nausea and vomiting, the delay of Wound healing, dysgenesia and alopecia.Some specific device
Official is likely to become susceptible, including heart, kidney and central nervous system (CNS).
It addition, use single chemotherapeutant seldom effective, because not every tumor cell is all to curing cancer
Effectively can be killed by single preparation.One reason for this is that, along with the development of cancerous cell, the incidence rate of sudden change also develop by
This may cause the generation of resistant phenotypes.Therefore, in most of the cases, for given a kind of modularization of clinical case research and development
Therapy is necessary.
The treatment of a kind of replacement scheme of companion animals cancer or improvement is existed one need, and especially those
There is in companion animals body the cancer of high incidence.
A kind of needs are equally existed for the substituting of the cancer in Canis familiaris L. class body or the property improved treatment.
To the lymphoma in treatment Canis familiaris L. body, mastocytoma, soft tissue sarcoma, angiosarcoma, osteosarcoma, squamous cell
Cancer, breast carcinoma, melanoma, histiocytoma and fibrosarcoma exist one to be needed.
A kind of replacement scheme of cat class cancer or the treatment of improvement are existed one need.
To the lymphoma in treatment cat body, mastocytoma, squamous cell carcinoma, breast carcinoma, angiosarcoma, osteosarcoma, fiber
There are one needs in sarcoma, sebaceous hyperplasia/adenoma.
Summary of the invention
The invention aims to solve in the demand is one or more, and in first aspect, it is provided that it is used for
Making the method that the cancer progression in a companion animals body minimizes, the method comprises the following steps:
One companion animals that will reduce wherein cancer progression is provided;And
One whole antibody including a variable domains or one fragment are provided in this animal body, are used for being attached to
One by the non-functional P2X of this animal expression7On receptor;
Thus minimize the cancer progression in this animal body.
At second aspect, the invention provides the side of a kind of cancer progression in minimizing a companion animals body
Method, the method comprises the following steps:
One companion animals needing treatment of cancer is provided;And
Formed a kind of for non-functional P2X in this companion animals body7One immunne response of receptor;
Thus minimize the cancer progression in this companion animals body.
In the third aspect, the invention provides the side of a kind of cancer progression in minimizing a companion animals body
Method, the method comprises the following steps:
One is provided to accept the non-self antigen binding site companion animals for treatment of cancer;
Formed a kind of for non-functional P2X in this companion animals body7The immunne response of receptor;
Most descend change cancer progression in this companion animals body.
In another aspect of the present invention, it is provided that following purposes:
One whole antibody including a variable domains, or one fragment is used for being attached to a non-functional
P2X7On receptor;Or
One P2X7Receptor, or a P2X7One fragment of receptor;
In the manufacture for a kind of medicament of companion animals treatment of cancer.
The most in yet another aspect, the invention provides following purposes:
One includes a variable domains whole antibody, or one fragment is used for being attached to a non-functional P2X7
Receptor;Or
One P2X7Receptor, or a P2X7One fragment of receptor;
For companion animals treatment of cancer.
Still at other aspect, the invention provides a kind of test kit or the compositions cancer in companion animals body and control
Treating, this test kit includes:
One includes a variable domains whole antibody, or one fragment is used for being attached to a non-functional P2X7
On receptor;Or
One P2X7Receptor, or a P2X7One fragment of receptor;
The written explanation in any one in a kind of method or above claim.
The other aspect of the present invention and be described in earlier paragraphs these in terms of further embodiment from following
Be given in explanation, by example and will become apparent referring to the drawings.
Brief Description Of Drawings
Fig. 1 .P2X7The aminoacid sequence of receptor.
Fig. 2. dog class and people P2X7The contrast of the aminoacid sequence of receptor.
The anti-E200 antibody response that Fig. 3 .ELISA (enzyme-linked immunosorbent assay) detects.
The detailed description of embodiment
To mention now certain embodiments of the present invention in more detail.Although the present invention will retouch in conjunction with these embodiments
State, it will be appreciated that be not intended as limiting the invention to these embodiments.On the contrary, it is contemplated that will cover as by right
All replacement schemes, amendment and the equivalent can being included within the scope of the invention defined in claim.
It will be appreciated by those skilled in the art that similar or identical to described here those many methods and material
Material, they may be used in the practice of the present invention.The present invention is limited to absolutely not these described methods and material.
It will be appreciated that the present invention disclosing in this manual and defining expand to mentioned or from context or
All alternative combinations of two or more animal character obvious in accompanying drawing.All these different combinations constitute the present invention
Different alternative aspect.
All patents mentioned hereby and publication are combined in this by quoting in full with it.
A defines
For explaining the purpose of this specification, defined below will apply generally and in due course, the odd number used
Term will also include plural number and vice versa.In listed any definition and any document punching being incorporated herein by reference
In the case of Tu, the definition being listed below will be preferential.
As used herein, unless the context requires otherwise beyond, term " includes (comprise) ", and this word
Variant, such as, " include (comprising) " and " including (comprises) " and " including (comprised) " not purport
Getting rid of other additive, component, integer or step.
" companion animals " typically refers to the animal that is " company " of the animal of house pet or a people.Cat (cat) and Canis familiaris L.
(dog) is example.
" purinoceptor " typically refers to a kind of receptor using purine (such as ATP) as part.
“P2X7Receptor " it is often referred to a purinoceptor formed by three protein protomers or monomer, at least one of which institute
State monomer and there is an aminoacid sequence the most as shown in Figure 1 or dog sequence the most as shown in Figure 2.Arrive this
P2X7The degree that receptor is formed by three monomers, it is one " trimer " or " trimer ".“P2X7Receptor " can be to retouch as follows
The function stated or non-functional receptor.“P2X7Receptor " contain the P2X of natural generation7Receptor variant, wherein P2X7Monomer is
Splice variant, allele variant and include the formation P2X of natural generation7The truncate of receptor or the monomer of secreted form
Isotype (form being such as made up of extracellular domain sequence or the form of its truncate), the variant form (example of natural generation
As, alternately splicing form) and the allele variant of natural generation.In certain embodiments of the present invention, it is disclosed in
This natural sequence P2X7Monomer polypeptide is the nature of maturation or the total length including the full length amino acid sequence shown in Fig. 1
Sequences polypeptide, or dog sequence the most as shown in Figure 2.In certain embodiments, this P2X7Receptor can have one
Adorned aminoacid sequence, the most in FIG shown in sequence in different aminoacids or one the most as shown in Figure 2
Dog sequence can be replaced, delete or may be inserted into a residue.
" functional P2X7Receptor " typically refer to the P2X with binding site or crack for being attached on ATP7Receptor
A kind of form.When being attached on ATP, this receptor defines non-selective sodium/calcium channel, and this Channel-shifted is poroid to one
Structure, this structure makes calcium ion can enter in cytosol, and one result can be programmed cell death.Normally
In stable state, functional P2X7The expression of receptor is usually limited to experience the cell of programmed death, such as thymocyte cell, dendron shape
Cell, lymphocyte, macrophage and mononuclear cell.Some functional P2X can also be there are on erythrocyte7By body surface
Reach.
" non-functional P2X7Receptor " generally refer to P2X7A kind of form of receptor, this form has a configuration and thus should
Receptor can not form an apoptosis hole.What one example occurred in these monomers one or more has one at Pro210
(according to SEQ No. ID: 1) in the case of individual isomer of taking advantage of a situation.In the mankind or non-human mammal monomer, this isomerization
It is probably and produces from any molecular events causing this monomer misfolding, including sudden change or the exception of such as monomer basic sequence
Post translational processing.One result of isomerization is that in the one or more ATP-binding site on this trimer, this receptor is not
Can be attached on ATP, and thus expand the opening of this passage.Specifically, when in three monomers is by mistakenly
Pack and therefore destroy two ATP-binding site.In these cases, this receptor can not form hole and which has limited calcium
Ion can enter into the degree in cytosol.Only maintain passage portion activity.Non-functional P2X7Expression of receptor is extensively
On general epithelial cancer and hemopoietic cancer.
" E200 epi-position " generally refers to one and is present in a non-functional P2X7An epi-position on receptor.The mankind
In, this sequence is GHNYTTRNILPGLNITC.At dog apoplexy due to endogenous wind, this sequence is GHNYTTRNILPDINITC.
" E300 epi-position " generally refers to one and is present in a non-functional P2X7An epi-position on receptor.The mankind and
Dog apoplexy due to endogenous wind, this sequence is identical, i.e. KYYKENNVEKRTLIKVF.
" multi-epitope " is commonly referred to as a kind of epi-position formed by the juxtaposition of E200 and E300 epi-position.E200 in dog class and
The point of the difference between the mankind is not included in dog class multi-epitope, it is meant that the composite table of dog class and the mankind is to be identical.To the greatest extent
Pipe cat P2X7Receptor sequence is not the most characterized, and Serology data in this confirms cat multi-epitope and dog and mankind's composite table
Position identical or generally as.
" antibody " or " immunoglobulin " or " Ig " are the γ ball eggs found in vertebrate blood or other body fluid
Albumin, they work in immune system with conjugated antigen, thus identify and/or neutralize exotic.
Antibody is typically the different tetramer glycoprotein being made up of two identical light (L) chains and two identical weight (H) chains.
Each L chain is connected on a H chain by the disulfide bond of a covalency.The two H chain (is depended on by one or more disulfide bond
Isotype in this H chain) it is connected to each other.Each H and L chain also has disulphide bridges in the chain being regularly spaced apart.
H and L chain defines specificity lg domain.More specifically, each H chain has about variable domains at N end
(VH), it is three constant domain (C afterwardsH) (for each α and γ chain) and four CHDomain (for the isotype of μ and ε).Often
Individual L chain has a variable domains (V at N endL), it is a constant domain (C at its other end afterwardsL)。VLWith VHComparison and
CLThe first constant domain (C with heavy chainH1) comparison.
Antibody can be assigned to different classifications or isotype.Exist the immunoglobulin of five kinds: IgA, IgD,
IgE, IgG and IgM, have the heavy chain being respectively designated as α, δ, ε, γ and μ.γ and α classification is based at CHSequence and function aspects
Smaller difference and be further separated into multiple subclass, the such as mankind express following subclass: IgG1, IgG2, IgG3, IgG4, IgA1,
And IgA2.L chain aminoacid sequence based on its constant domain from any vertebrate class can be designated as two substantially
One of different type, referred to as κ and λ.
This constant domain includes Fc part, whole two H chains that this part includes being combined by disulfide
Carboxy terminal half.Determined the effector function of antibody (such as ADCC) by the sequence in Fc district, this district is also by certain
The part that the Fc receptor (FcR) found on the cell of type identifies.
VHAnd VLPairing together form one " variable region " or " variable domains ", including heavy chain or the light chain of antibody
Amino terminal domain.The variable domains of heavy chain can be referred to as " VH”.The variable domains of light chain can be referred to as " VL”。V
Domain comprises one " antigen binding site ", and this antigen binding site have impact on antigen and combines and define a kind of concrete anti-
The body specificity to its concrete antigen.V district has striden across about 110 amino acid residues and has been referred to as by 15-30 is amino acid whose
The most constant stretch section (the relatively invariant stretch) composition of framework region (FR) (normally about 4), this is relative
Constant stretch section is referred to as the shorter of respective " hypervariable region " (normally about 3) typically with 9-12 amino acid long by the most variable
Region separately.These FR major parts take β sheet configuration and hypervariable region to define the ring connecting β chip architecture, and at some
In the case of define the part of β chip architecture.
" hypervariable region " refers to the region in an antibody variable territory, these regions in terms of sequence be high become and/or
Form the ring structurally defined.Generally, antibody includes six hypervariable regions;Three at VHIn (H1, H2, H3), and three at VL
In (L1, L2, L3).
" framework " or " FR " residue is in addition to those the variable domains residues beyond some hypervariable region residues defined herein.
" for forming the peptide of antigen binding site " typically refers to form the structure giving antibody specificity for antigen
The peptide of type.Example includes whole antibody or whole antibody dependency structure, including whole antibody fragment, its variable knot of a variable domains
Structure territory and fragment, including light and heavy chain, or include some but the most all of hypervariable region or the light and sheet of heavy chain of constant region
Section.
" antigen binding site " generally refers to include at least antigen combined function being given necessary to a V structure territory high
Become district and a molecule of framework region.Stating in method in this, antigen binding site may be at an antibody or
The form of one antibody fragment (such as one dAb, Fab, Fd, Fv, F (ab ')2Or scFv).
" complete " or " entirely " antibody is to include antigen binding site, together with CLAnd at least heavy-chain constant domains CHI、CH2 Hes
CHThe antibody of 3.Constant domain can be constant domain (such as, human native sebquence's constant domain) or its aminoacid sequence of native sequences
Variant.
" include the whole antibody fragment of a variable domains " and include Fab, Fab ', F (ab ')2, and Fv fragment;Double-strand resists
Body, linear antibodies, single-chain antibody molecules;And the multi-specificity antibody from antibody fragment formation.
" Fab fragment " is by the Variable domain (V of whole L chain Yu H chainH) and the first constant domain (C of a heavy chainHI)
Composition.It is unit price that each Fab fragment combines relative to antigen, i.e. it has single antigen binding site.
" Fab ' fragment " is at C with the difference of Fab fragmentHThe c-terminus of I domain has extra little residue, bag
Include one or more cysteine from antibody hinge region.Fab '-SH names for Fab ' at this, wherein this constant domain
One or more cysteine residues with a free sulfydryl.
“F(ab′)2Fragment " generally correspond to the Fab that two disulphide with bivalent antigen combination activity connect
Fragment and remain can crosslinking antigen.
" Fv " is to comprise a complete antigen identification and the minimum antibody fragment of binding site.This fragment is by with the most non-
One heavy chain of non-covalent association and a light chain Variable domain dimer composition.
Planting apoplexy due to endogenous wind, a heavy chain and a light variable domains a scFv (scFv) can be soft by one
Property peptide junctional complex covalently bound so that this light chain and heavy chain can be at one " dimer " knots being similar to two chain Fv kinds
Structure associates.Exhaling six Gao Bianhuan (3 rings are each from H and L chain) from the folding of the two domain, these rings help
It is used for the antigen-binding specificity that antigen combines and gives antagonist in amino acid residue.
" scFv " is also abbreviated as " sFv " or " scFv ", is to include connecting the V forming a single polypeptide chainHAnd VLAnti-
The antibody fragment of binding domains.Preferably, this scFv polypeptide further includes at this VHAnd VLA polypeptide between domain is even
Connect thing so that this scFv can define the desired structure combined for antigen.
" single variable domains " is the half (only including three CDR for antigen-specific) of Fv, and this Fv has identification
And the ability of conjugated antigen, although lower than the affinity of whole binding site.
" double-chain antibody " refers to the antibody fragment with two antigen binding sites, and these fragments include being connected to same
Polypeptide chain (VH-VLA light variable domains (V in)LHeavy-chain variable domains (V on)H).Little antibody fragment passes through
At this VHWith VLBuild between domain and there is the sFv fragment (seeing above paragraph) of short junctional complex (about 5-10 residue) and make
Standby to achieve the interchain pairing in V structure territory but be not pairing in chain, consequently leads to a bivalent fragment, i.e. have two
The fragment of individual antigen binding site.
Double-chain antibody can be bivalence or bispecific.The double-chain antibody of bispecific is two " crossover " sFv
The heterodimer of fragment, the wherein V of the two antibodyHWith VLDomain exists on different polypeptide chains.Three chain antibodies and four
Chain antibody is the most known in the art.
" antibody of separation " be the component from the environment that it is pre-existing in identify and separate and/or reclaim anti-
Body.Pollution components is will to disturb the material of the therapeutic use for antibody and can include enzyme, hormone and other albumen
Matter solute or non-proteinaceous solute.
" monoclonal antibody " refers to a kind of antibody that the colony of basically homogeneous antibody obtains, i.e. include this colony
Animal's antibody be identical, in addition to the sudden change of the possible natural generation that may exist with less amount.Monoclonal anti
Body is high degree of specificity, its single antigen site being directed on antigen or determinant.In addition to its specificity, single
Advantageously they can be synthesized clonal antibody by other antibody not comtaminatedly.Monoclonal antibody can pass through hybridoma side
Prepared by the science of law.These " monoclonal antibodies " can also separate from phage antibody library from using these technology.
Monoclonal antibody in this includes " chimeric " antibody, wherein a part for weight and/or light chain with derived from one
Specific kind of antibody or the corresponding sequence that belongs to an antibody specific kind or subclass is identical or homology, and this or many
The remainder of individual chain be with the antibody derived from another kind or belong to another antibody type or subclass antibody together with this
Corresponding sequence in the fragment of kind of antibody is identical or homology, as long as they show desired biological activity.
Term " anti-P2X7Receptor antibody " or " it is attached to P2X7Antibody on receptor " refer to enough affinitys
It is attached to P2X7On receptor so that this antibody diagnoses as one and/or therapeutic agent is at targeting P2X7Receptor is (the most non-functional
Property P2X7Receptor) in be useful antibody.Preferably, by one P2X7Receptor antibody is attached to unconnected P2X7Receptor egg
Degree on Bai less than this antibodies such as the most measured (such as by radioimmunoassay (RIA)) to P2X7Pact on receptor
10%.In certain embodiments, it is attached to P2X7Dissociation constant (Kd) < 1 μM that antibody on receptor has, < 100nM, <
10nM, < 1nM or < 0.1nM.Anti-non-functional P2X7Receptor antibody is typically have these Serological Characterizations some or all of
And it is attached to non-functional P2X7On receptor rather than functional P2X7Antibody on receptor.
A kind of " affinity maturation " antibody is to have resisting of one or more change in one or more hypervariable region
Body, this change, compared with the maternal antibody not having one or more that change, result in the antibody affinity to antigen
Improvement.The preferably antibody of affinity maturation has the affinity for target antigen of nanomole or even picomole.Affine
The antibody that power is ripe is produced by program known in the art.
" closure " antibody or " antagonist " antibody are suppression or antigen bioactive reducing this antibodies
Antibody.Preferably blocking antibody or antagonist antibodies substantially or entirely inhibits the biological activity of this antigen.
As used herein, at least one during " agonist antibody " is a kind of functional activity simulating polypeptide interested
Antibody.
" binding affinity " typically refers to the single binding site gametophyte in connection at a molecule (such as antibody)
The intensity of the noncovalent interaction summation between (such as, antigen).Except as otherwise noted, as used in this " in conjunction with parent
And power " refer to inherent binding affinity, reflect the one between a member combined (such as, antibody and antigen)
The interaction of 1:1.Molecule X generally can pass through dissociation constant (K for the affinity of its gametophyte Yd) represent.Can pass through
Methods known in the art measure affinity, including described here those.Low-affinity antibody is attached to resist the most lentamente
Former upper and tend to dissociate easily, and high-affinity antibody is attached on antigen the most quickly and tends to keep
In conjunction with more long.The many kind methods measuring binding affinity are to it known in the art, any of which method to may be used for the present invention
Purpose.
" treat " both that be commonly referred to as therapy for treating and prevention or preventive measures.
The animal needing treatment includes having had optimum, preneoplastic or those companies of non-metastatic tumor
With wherein stoping those of its cancer morbidity or recurrence.
Purpose or the result for the treatment of can reduce cancerous cell number;Reduce primary tumor size;Suppression is (i.e. necessarily
Slow down in degree and preferably stop) cancer cell infiltration is to peripheral organs;Suppression (slows down and preferably the most to a certain extent
Ground stops) neoplasm metastasis;Suppress tumor growth to a certain extent;And/or alleviate to a certain extent and be associated with this imbalance
Symptom in one or more.
The persistent period that can be survived by evaluation, the time of progression of disease, answer speed (RR), the persistent period of response
And/or quality of life measure effect for the treatment of.
In one embodiment, the method is useful especially to the time of prolongation progression of disease.
In one embodiment, the method survival rate to prolongation animal, deposit together with getting nowhere including total time-to-live
Motility rate, is useful especially.
In one embodiment, the method is useful especially for providing one to treating complete response, thus rings
Should disappear in all cancer signs for the treatment of.This most always means that cancer has been cured.
In one embodiment, the method is useful especially for providing a part response to treatment, thus rings
A fall should have been had in treatment, the degree of cancer in the size of one or more tumors or pathological changes or in the body
Low.
" precancer " or " preneoplasia " is commonly referred to as typically being carried out into or developing into a kind of patient's condition of a kind of cancer
Or growth." precancer " growth is likely to be of the cell cycle regulating with exception, breeds or be divided into the cell of feature, and these are thin
Born of the same parents can be determined by the mark of cell cycle.
" patient's condition that [with cancer] is associated or symptom " can be that the result as cancer produces, before cancer or
It is by any pathology of cancer progression.Such as, when this cancer is skin carcinoma, this patient's condition or related symptoms can be microorganism senses
Dye.When this cancer is a kind of secondary tumors, and this patient's condition or symptom can relate to the organ with the relevant organ of neoplasm metastasis
Dysfunction.In one embodiment, Therapeutic Method described here be the patient's condition in an animal body or symptom
Littleization or treatment, this symptom or the patient's condition are relevant to the cancer in this animal body.
" non-autologous " molecule, such as " non-autologous " antigen binding site or " non-autologous " antibody typically refer to one by
External generation or the molecule of external source, wherein this molecule will be provided, such as, be used for treating.As an example, synthesis
Or the molecule of restructuring is " non-autologous ".Further, one results from an animal and is applied to another animal for controlling
The molecule treated is " non-autologous "." non-autologous " antigen binding site and antibody can be used for continuing of immunity according to the present invention
Holding property shifts, such as, occur when antibody infusion.On the contrary, one produce in an animal body and with this molecular therapy this move
The molecule of thing, it is common that a kind of " autologous " or " endogenous " molecule.One example of " autologous " molecule be one be produced from or by
A kind of antigen binding site that immunogenic adaptive immune response is produced or antibody.
" level of the non-self antigen binding site of circulation " in animal body typically refers to antigen binding site at body fluid
In concentration, preferably at peripheral blood.
" the non-self antigen binding site level that the most generally can not detect " typically refers to exogenous antigen knot
These antigens when the concentration of conjunction site (i.e. those have been used by adoptive transfer) at least uses this antigen binding site
The half of binding site concentration in the circulating cycle, it is therefore preferable to the 25% of described concentration or 10% or 5% or 1%, or separately
The outer 0.001mg/kg less than this animal.This phrase is also refer to a kind of situation, interim has been applied for cancer immunotherapy
Antigen binding site can not be detected at all.
The cancer that " generally can not detect " be typically its middle finger treatment decreased the size of a kind of cancer, volume or
The situation of other physical measurements so that using relevant criterion detection technique (such as living imaging), this cancer is as this treatment
Result is not clearly can to detect.This phrase is also refer to the situation that wherein this cancer can not be detected at all.
" form an immunne response " and typically refer to cause via adaptive immune system or inducing antigen-specific immunity.
As being commonly understood by the art, the induction of antigen specific immune is different from the adoptive transfer of immunity, by exogenous
Or non-autologous property antibody use the example that the standard cancer immunization therapy carried out is the latter.
B. the cancer immunotherapy carried out by antibody infusion
Although non-functional P2X7Receptor distribution expression pattern in normal, the preneoplastic or human tissue of tumor exists
It is to understand the when of the present invention, but about non-functional P2X7(especially companion animals is such as non-human animal for receptor
Cat and Canis familiaris L.) in tissue expression, be seldom known.
Specifically, the trimer non-functional receptor whether biological tissue in companion animals body is expressed and concrete
It is unknown at which tissue expressing.Further, this expression whether can find in cancerous tissue and if it find that,
This expression can be limited to cancerous tissue be which kind of degree be unknown.Therefore, whether some companion animals cancer is expressed non-functional
Property P2X7Receptor, or be whether all unknown by having notable toxicity with the treatment of antibody to normal cell.
Further, whether the cancer specific epitopes observed on live body cancerous tissue in the mankind is present in companion animals cancer
Disease tissue is unknown.The present invention when, this is with how to produce the problem of anticancrin in companion animals body be straight
Connect relevant.Particularly, cat P2X7Receptor sequence is entirely the unknown.
Known Canis familiaris L. P2X7Sequence and mankind P2X7Receptor is dramatically different, at it corresponding to the region of E200 in people in Canis familiaris L. sequence
In crucial proline 210 (the known non-functional producing people's receptor in human body) is added carboxyl immediately, it is known that this Canis familiaris L. sequence is such as
As in human body, substitute neutral glycine with electronegative aspartic acid non-conservation.Further, Canis familiaris L. and the mankind it
Between in other aminoacid differences, it is known that at least about 55% in these is that non-conservation substitutes, and has one to be inserted in the mankind
In do not find.Specifically participate in Fig. 2.
In sum, when in the present invention, unknown non-functional P2X7Receptor whether be present in companion animals (include Canis familiaris L. and
Cat) in, therefore unknown P2X7It is dynamic for accompanying whether receptor can be used as a biomarker as having been used to the mankind
Treatment of cancer in object.
As described in this, ladies and gentlemen inventor is it has been shown that cultivate for a peptide immunity with E200 epi-position
The treatment of the sheep antibody kinds cancer to having more high incidence in companion animals body be highly effective, and have
Minimal side effect or toxicity.Thus ladies and gentlemen inventor has realized that some cancerous cell of living expresses non-functional in Canis familiaris L. and cat body
P2X7Receptor.In view of minimum toxicity, the expression of these receptors seems to be limited to the preneoplastic or tissue of tumor.It addition, also
And despite difference (such as at Canis familiaris L. and mankind P2X7Between sequence), but these companion animals receptors seem to have like thereon
Find an extracellular configuration of mankind's E200 epi-position.
It addition, and surprisingly, ladies and gentlemen are inventor has recognised that anti-xenogenesis P2X7Immunogen and the xenogenesis cultivated
Antibody is highly effective to the cancer in treatment companion animals (including cat and Canis familiaris L.).
Therefore, in first aspect, the invention provides a kind of cancer progression in a companion animals body and minimize
Method, the method comprises the following steps:
One companion animals minimizing wherein cancer progression is provided;And
One whole antibody including a variable domains or one fragment are provided in this animal body, are used for being attached to
One by the non-functional P2X of this animal expression7On receptor;
Thus minimize the cancer progression in this animal body.
At other aspect, the invention provides a kind of whole antibody or one fragment in one for companion animals cancer
Purposes in the manufacture of the medicament for the treatment of, this whole antibody or one fragment include a variable domains, are used for being attached to one
Individual non-functional P2X7On receptor.
Still at other aspect, the invention provides a kind of whole antibody or one fragment for one companion animals for the treatment of
The purposes of internal cancer, this whole antibody or one fragment include a variable domains, be used for being attached to one non-functional
Property P2X7On receptor.
Method according to the first aspect of the invention, an animal to be treated can be to have accepted or be
Any animal indicating the therapeutic antibodies for tumor will be accepted.
In an embodiment of first aspect, the antigen binding site of an antibody can be to distinguish functional and NOT function
Can property P2X7The antigen binding site of receptor, is hereby incorporated into non-functional receptor rather than functional receptor.These antigen is tied
The example closing site is bonded to those of E200 epi-position, E300 epi-position or multi-epitope, such as at PCT/AU2002/
000061、PCT/AU2002/001204、PCT/AU2007/001540、PCT/AU2007/001541、PCT/AU2008/
001364, in PCT/AU2008/001365, PCT/AU2009/000869 and PCT/AU2010/001070, all these all
It is incorporated by reference.
One antigen binding site can with the form of the form or a whole antibody fragment of taking a whole antibody (such as
One Fab, Fab ', F (ab ')2And Fv), a scFv or a single variable domains.
Relative to this, will to accept it for the companion animals for the treatment of of cancer can be homology, of the same race to antigen binding site
Different system or xenogenesis.
Typically, this antigen binding site is non-autologous property or external source, it is meant that in the side according to the present invention
Found or separated beyond the animal of method treatment.
This antigen binding site can be affine maturation.
This antigen binding site can have many species specificity or quantivalence.
This antigen binding site can be adapted, and thus fits through a method selected and uses.
This antibody can be a whole antibody of any isotype.This antibody can be from monoclonal antibody or Anti-TNF-α
The antibody obtained in serum.This antibody can produce from hybridoma, or by recombinant expressed, or can obtain from serum
(such as can obtain from a kind of mammal, particularly people or mice).This antibody can also obtain from a kind of birds.
This antibody can be chimeric, a kind of antibody comprising human variable-domain and non-human constant domain.
Alternately, it can be humanized, i.e. by non-human CDR is grafted on a human antibodies framework the anti-of formation
Body.Still further, this antibody can be full people source.
This antibody can be modified relative to effector function and thus strengthen, such as, be used for strengthening this antibody in treatment cancer
Effectiveness in disease.
In the case of this antibody is a kind of antibody fragment, this antibody fragment is selected from lower group, and this group is made up of the following:
dAb、Fab、Fd、Fv、F(ab’)2, scFv and CDR.
Hereinafter the value of dosage, dose frequency, route of administration etc. are described in detail.
Prepare antibody and the method to its animal in need of being used by antibody is ripe for those skilled in the art
Know, or easily determined by those skilled in the art.Route of administration it may be that such as, oral, parenteral (example
Such as intravenous, intra-arterial, intraperitoneal, intramuscular, subcutaneous, Intradermal, rectum or vagina), by sucking or local application.Use
One form can be a kind of solution for injection, and especially for intravenous injection or intra-arterial injection or instillation, this solution includes
A kind of buffer (such as acetate, phosphate or citrate buffer), a kind of surfactant (such as Polysorbate), appoint
Selection of land one stabilizer (such as albumin).In additive method, can directly by antibody delivery to disease site, thus increase
Sick cell or the exposure of tissue antagonist.
Preparation for parenteral administration include sterilized water (aqueous carrier includes water, alcohol/aqueous solution, emulsion or suspension,
Including saline and buffer medium) or non-aqueous (nonaqueous solvent is propylene glycol, Polyethylene Glycol, vegetable oil (such as olive oil) and can
Injection organic ester (such as ethyl oleate)) solution, suspension and emulsion.Pharmaceutically acceptable carrier includes 0.01M-0.1M
And the phosphate buffer of preferably 0.05M or 0.9% saline.Other common parenteral vehicle include sodium radio-phosphate,P-32 solution, woods
Grignard glucose, glucose and sodium chloride, Lactated Ringer'S Solution or fixing oil.Intravenous vehicles includes fluid and nutrient
Supplement, electrolyte replenisher (such as based on woods grignard glucose those), and the like.Can also exist preservative and
Other additives, such as antimicrobial, antioxidant, chelating agen and noble gas, and the like.
More specifically, it (is water solublity time suitable that the pharmaceutical composition being suitable for injectable purposes comprises aseptic aqueous solution
) or dispersion and the sterilized powder of the instant preparation for sterile injectable solution or dispersion, in this case,
Said composition must be aseptic and should be the fluid existed with the degree of easily injection.It should be to manufacture and depositing
Contamination that is stable and that be preferably for microorganism (such as antibacterial and fungus) under the conditions of storage and preserve.This carrier can
Be containing such as water, ethanol, polyhydric alcohol (such as, glycerol, propylene glycol and liquid macrogol, and the like) and
The solvent of their applicable mixture and disperse medium,.Suitable mobility can be such as by using a kind of coating (such as ovum
Phospholipid), by keeping particle diameter required in the case of a dispersion and by using surfactant to maintain.For
Applicable preparation in this Therapeutic Method disclosed is described in Remington ' s Pharmaceutical Sciences (Lei Ming
Dun Shi pharmaceutical science), Mack Publishing Co. company, in 16 editions (1980).
The effect preventing microorganism can pass through different antibacteriums and antifungal, such as metagin, three
The chlorine tert-butyl alcohol, phenol, ascorbic acid, thimerosal and the like realize.In many cases, it may be preferred that in this combination
Thing includes isotonic agent, such as sugar, polyhydric alcohol (such as mannitol, sorbitol) or sodium chloride.The prolongation of Injectable composition is inhaled
Receipts can be by including the medicament of a kind of delayed absorption in the composition, and such as aluminum monostearate and gelatin realize.
Under any circumstance, sterile injectable solution can be by by a kind of reactive compound (example in appropriate solvent
As, antigen binding site) be combined with a kind of or a combination composition listed herein with required amount, connect
Filtration sterilization to prepare.Generally, prepare dispersion by being attached to by this reactive compound in a kind of sterile carrier, should
Carrier contains a kind of basic dispersion body medium and required other compositions from those listed above.Make being used for
In the case of the sterilized powder of standby aseptic Injectable solution, preferred preparation method is vacuum drying and lyophilization, this
Create active component and add any extra powder from the composition desired by its above sterilefiltered solutions.To being used for
The preparation of injection is processed, and is filled in container such as ampoule, bag, bottle, syringe or bottle, and according to this area
Seal under known aseptic condition.Additionally, these preparations can be by the packaged of test kit and sell.Such system
Divine force that created the universe product preferably have label or package insert (package insert), indicate compositions related for treatment suffer from imbalance
Or the experimenter being susceptible to suffer from imbalance is useful.
The compositions of the present invention depend on many different factors for the effective dose treating as described in this imbalance and
Changing, including using the physiological status of means, target location, patient, whether patient be human or animal, the other drug used is controlled
Treat, and treatment is preventative or curative.Therapeutic dose can use known to those of ordinary skill in the art
Conventional method progressively increases to optimize safety and effect.
For with a kind of Antybody therapy, some is lacked of proper care, the scope of dosage can be such as from about host's body weight
0.0001mg/kg to 100mg/kg, and more generally 0.01mg/kg to 5mg/kg (such as 0.02mg/kg, 0.25mg/kg,
0.5mg/kg, 0.75mg/kg, 1mg/kg, 2mg/kg, etc.).Such as, dosage can be 1mg/kg body weight or 10mg/kg body weight or
In the range of 1mg/kg-10mg/kg, preferably at least 1mg/kg.Dosage intermediate value in range above is also intended to the present invention
In the range of.Can to experimenter every day, every other day, weekly or rule of thumb analyze any other scheme determined and use this agent
Amount.Exemplary treatment requires to use with multiple dosage within a period (such as, at least six moon) extended.Extra example
Property therapeutic scheme require once every two weeks or monthly or every 3 to 6 months applied onces.Exemplary dose scheme includes
1mg/kg-10mg/kg or 15mg/kg sustained continuous sky, 30mg/kg or weekly 60mg/kg every other day.In certain methods, simultaneously
Use two or more antigen binding sites with different binding specificities, in this case, every kind used
The dosage of antigen site falls in specified scope.
Can use for being attached to an expression non-functional P2X on a cell in several cases7Receptor
Antibody.Interval between single dose can be weekly, monthly or every year.Interval can also is that irregular, as by surveying
Measure indicated by the blood level of the target polypeptides in patient or target molecule.In certain methods, dosage is adjusted with
Realize the plasma polypeptide concentration of 1 μ g/mL-1000 μ g/mL, and be 25 μ g/mL-300 μ g/mL in certain methods.Alternative
Ground, this antibody can be used as sustained-release formulation, needs using of lower frequency in this case.Dosage and frequency
Depend on that the half life of the antibody in patient changes.The half life of antibody can also via be fused to a stable polypeptide or
Extend in part, such as albumin or PEG.Generally, humanized antibody demonstrates the longest half life, is followed by chimeric antibody
And non-human antibody.In one embodiment, this antibody can be used by unconjugated form.In another embodiment, should
Antibody can be used by unconjugated form and repeatedly use.In some treatment use, sometimes require higher dosage (such as,
The up to anti-P2X of 400mg/kg7Binding molecule, the antibody of such as every dosage), with shorter interval until the progress of disease reduces or
Terminate, and show the improvement of disease symptoms partially or completely preferably of up to patient.When this antibodies is to a kind of radiation
Time on property isotope or cytotoxic drug, this amount can be lower (i.e. 2 to 3 Logarithmic degree lower) of some Logarithmic degree.
Therapeutic agent can pass through parenteral, locally, intravenous, oral, subcutaneous, intra-arterial, intracranial, intraperitoneal, intranasal or
Intramuscular means are used, and for preventative and/or therapeutic treatment, in certain methods, medicament are injected directly into wherein NOT function
Can property P2X7In the concrete tissue that recipient cell has built up, such as intracranial injection.Intramuscular injection or venoclysis are for antibody
To use be preferred.
A kind of antibody can be optionally incorporated in the treatment of imbalance or the patient's condition needing treatment (the most preventative
Or curative) other medicaments and use.Example is those medicaments being normally used for chemotherapy or radiotherapy in oncology.Additionally
Ground or alternately, this antibody or medicament can before the excision of tumor or tissue or the operative treatment removed, in or
Used later.
According to the first aspect of the invention, in one embodiment, the method may be used for treating cancer, in particular for
The therapeutic treatment of cancer.
In one embodiment, the purpose of this treatment or result be following in one or more:
Reduce the number of cancerous cell;
Reduce the size of primary tumo(u)r;
Suppression (slow down the most to a certain extent or preferably stop) cancerous cell penetrates into peripheral organs;
Suppression (slow down the most to a certain extent or preferably stop) neoplasm metastasis;
Suppress tumor growth to a certain extent;
Alleviate one or more in the symptom relevant with this imbalance to a certain extent.
In one embodiment, the method for a first aspect of the present invention is for extending the time of progression of disease.
In one embodiment, the method for first aspect is for extending the survival rate of animal, including total time-to-live even
With progresson free survival rate.
In one embodiment, the method for first aspect for provide one to treatment complete answer, thus in response to
All cancer signs for the treatment of have disappeared.
In one embodiment, the method for first aspect for provide to treatment a part response, thus in response to
Treatment, the degree of cancer in the size of one or more tumors or pathological changes or in the body has had a reduction.
In one embodiment, it is necessary to the animal for the treatment of includes suffering from optimum, before cancer or non-metastatic tumor
Those.
In one embodiment, this cancer is precancerous or preneoplastic.
In one embodiment, this cancer is secondary cancer or metastatic tumor.This secondary cancer may be located at any device
Official or tissue, and particularly those have the organ or tissue of the most higher hemodynamic pressure, such as lung, kidney, pancreas
Gland, intestinal and brain.
In one embodiment, this cancer can generally can not detect.
This companion animals can be a cat or Canis familiaris L..But, in view of for the people's albumen for non-human primate receptor
The cross reactivity of antibody cultivated, ladies and gentlemen are inventors have realised that other have identical with the mankind remote phylogenetic
Non-human mammal can benefit from the present invention.In one embodiment, this companion animals is a kind of high value animal or good
Plant animal.One example is a dry goods.
Typically it is desirable to the cancer for the treatment of or precancer are to have more high incidence in a given companion animals body
Cancer.Such as, when this companion animals is a Canis familiaris L., this cancer can be lymphoma, mastocytoma, soft tissue meat
Tumor, angiosarcoma, osteosarcoma, squamous cell carcinoma, breast carcinoma, melanoma, histiocytoma, carcinoma sarcomatodes or fibrosarcoma.
When this companion animals is a cat, this cancer can be lymphoma, mastocytoma, squamous cell carcinoma, breast
Cancer, angiosarcoma, osteosarcoma, fibrosarcoma or sebaceous hyperplasia/adenoma.
Other examples of cancer are described in Table I or include that blastoma (includes that medulloblastoma, retina are female thin
Born of the same parents' tumor), sarcoma (including liposarcoma and synovial cell sarcom), neuroendocrine tumor (include carcinoid tumor, gastrinoma and pancreas
Islet cell tumor), mesothelioma, schwannoma (including acoustic neuroma), meningioma, adenocarcinoma, melanoma, leukemia or lymphoid malignant
Tumor, pulmonary carcinoma (including small cell lung cancer (SGLG), nonsmall-cell lung cancer (NSGLG), adenocarcinoma of lung and pulmonary's squamous cell carcinoma),
Peritoneal cancer, hepatocarcinoma, stomach or gastric cancer (including gastrointestinal cancer), cancer of pancreas, glioblastoma, cervical cancer, ovary
Cancer, hepatocarcinoma, bladder cancer, hepatoma, breast carcinoma (including transitivity breast carcinoma), colon cancer, rectal cancer, colorectal carcinoma, intrauterine
Film cancer or uterus carcinoma, salivary-gland carcinoma, renal cancer or renal carcinoma, carcinoma of prostate, carcinoma vulvae, thyroid carcinoma, hepatocarcinoma, anus cancer, penis
Cancer, carcinoma of testis, the esophageal carcinoma, tumor of bile duct are together with head and neck cancer.
Applied dose and frequency can depend on that this treatment is preventative or curative and change.Preventative
In application, the compositions including antibody or its mixture is used not in morbid state or disease state patient with
Strengthen the resistance of patient.Such a amount is defined as " prevention effective dose ".In this use, accurate amount takes again
Certainly in health status and the general immunity of this animal, but generally scope is from the every dosage of 0.1mg to 25mg, especially
The every dosage of 0.5mg to 2.5mg.Relatively low-dose is to use through long period with interval less frequently.Some animals are for it
Remaining life and continue to accept treatment.
In treatment use, sometimes require that higher dosage is (such as, from the binding molecule of about 1mg/kg to 400mg/kg, example
Such as the antibody of every dosage, dosage is more generally used from 5mg to 25mg for radioimmunoassay conjugate, and for cell
The more high dose of the molecule that toxin-medicine combines) with shorter interval, until the progress of disease reduces or terminates and the most straight
The improvement of disease symptoms partially or completely is shown to animal.
In one embodiment, associated cancer in this antibodies another kind indicates the companion animals body for needing treatment
Chemotherapy or antineoplastic compound provide together.The example of these compounds and relevant instruction describes in Table 1.
In another embodiment, this antibody at one before the clinical operation of lower group, in or after provide, this group by with
Under every composition: surgical operation, radiotherapy, thermotherapy, photodynamic therapy, chemotherapy, gene therapy and immunization therapy.
C. the cancer immunotherapy carried out by immunity
At second aspect, present invention provide for making the one that the cancer progression in a companion animals body minimizes
Method, the method comprises the following steps:
One companion animals needing treatment of cancer is provided;And
Formed a kind of for non-functional P2X in this companion animals body7The immunne response of receptor;
Thus minimize the cancer progression in this companion animals body.
In the third aspect, present invention provide for making to receive accompanying of a kind of non-self antigen binding site
A kind of method that cancer progression in companion's animal body minimizes, for treatment of cancer, the method comprises the following steps:
There is provided a companion animals having accepted a kind of non-self antigen binding site, for treatment of cancer;
Formed a kind of for non-functional P2X in this companion animals body7The immunne response of receptor;
Thus minimize the cancer progression in this companion animals body.
In yet another aspect, the invention provides a kind of non-functional P2X7Receptor or its fragment are used for treatment one in one
Purposes in the manufacture of the medicament of the cancer in individual companion animals body, especially one have accepted a kind of non-self antigen and have combined
Site is for the animal for the treatment of of cancer, such as cat or Canis familiaris L..
In yet other aspects, the invention provides a kind of non-functional P2X7Receptor or its fragment are accompanied for treatment one
The purposes of cancer in companion's animal body, a kind of has accepted a kind of non-self antigen binding site for treatment of cancer
Animal, such as cat or Canis familiaris L..
In yet another aspect, the invention provides a kind of non-functional P2X7Receptor or its fragment one for treatment or
Suppress cancer progression in a companion animals body medicament manufacture in purposes, this companion animals has accepted a kind of anti-non-
Functional P2X7Receptor antigen binding site is used for treatment of cancer.
In an embodiment of the second and third aspect of the present invention, in this immunne response in this companion animals body
During formation, this companion animals can not have the non-self antigen binding site that can detect in the circulating cycle.Such as, the antibody of infusion
May be removed from blood plasma when immunity.It addition, when this immunne response is formed in this companion animals body, this
Companion animals can not have the cancer that can detect, such as, after a kind of antigen binding site is used this companion animals
As a result, when this immunne response is formed in this companion animals body, this cancer can have size, the quality generally reduced
Or other physical measurements.
According to the second and third aspect of the present invention, this immunne response may be formed by immunogen.This immunogen is permissible
Can induce a non-functional P2X by one7The P2X of receptor immunne response in this companion animals body7The shape of receptor
Formula, or a P2X7The form of the fragment of receptor provides.One non-functional P2X7Receptor is defined as being formed at phase
Adjacent correct packaging can not be in conjunction with at least one in three ATP-binding site on the interface between the monomer of ATP.This
Receptor can not expand the non-selective calcium channel opening to apoptosis hole.This immunogen can comprise can be at one main group
Knit and exist on histocmpatibility II quasi-molecule and/or can be with exempting from that a T or B-cell receptor or B cell film are combined
At least one sequence that epidemic disease globulin interacts.Typically, this companion animals is a cat or Canis familiaris L., in this case should
Immunogen can be provided by following form: a cat or Canis familiaris L. P2X7Receptor, or it is their ability to induction to P2X7The immunity of receptor should
The fragment answered.Canis familiaris L. P2X7Receptor sequence is illustrated in Fig. 2 in this.Typically, it is formed at the immunity in this companion animals body
Response is to non-functional P2X7Receptor is specific, in this case, defines nand function in this companion animals body
Property P2X7Receptor (i.e. non ATP bind receptor) reaction but not with functional P2X7Antibody that receptor (i.e. ATP bind receptor) reacts or
Cellular component.
In the preferred form of the second and third aspect of the present invention, this immunogen is supplied to this in an initial application
Companion animals, is consequently formed the response including that IgM produces.In other preferred form, it is supplied in initial application
This companion animals immunogen, is consequently formed the response including that IgM produces, in later time, and another relative to initial application
Outer use, use this immunogen, thus form the response including that IgG produces.In the present embodiment, typically,
When IgM level in circulation in companion animals body generally can not detect, there is immunogenic other using.
This immunne response that second and third aspect according to the present invention is formed can be a humoral response and/or cell
Response.Humoral response can include that B cell activates and cytokine generation, propagation to the plasmacytic conversion of secretory antibody, Th2
It is centrally formed and produces with isotype conversion, the affine maturation of B cell and/or memory cell.Cell response can include activating and resist
Former specific cell toxin T-lymphocyte, activating macrophage and natural killer cell and/or stimulation emiocytosis cell
The factor.The humoral response and/or the cell response that are formed in companion animals body can treat or alleviate in this companion animals body
Cancer, or minimize the cancer progression in this companion animals body.
In above-described embodiment of the second and third aspect of the present invention, this companion animals the antigen bound site accepted
Point can react with any biomarker being associated with cancer.Example includes anti-P2X7, especially non-functional P2X7, anti-
VEGF, especially VEGF A, C or D, Her-2, CD20 or other antigen binding site.Typically, this companion animals connect
The antigen binding site being subject to and P2X7Receptor, especially non-functional P2X7Receptor response.
In another embodiment of the second and third aspect of the present invention, it is provided that a kind of compositions is used for treating or being used for
Cancer progression in suppression companion animals body, said composition includes P2X7Receptor or its fragment.Preferably, said composition is further
Including a kind of carrier, excipient or diluent.Preferably, said composition farther includes a kind of adjuvant.At a preferred form
In, said composition makes when using this immunogen for the first time to this companion animals, it is possible to forms primary immune response and (includes that IgM produces
Raw), and make after using for the first time, when using this immunogen, it is possible to form the second immunne response (including that IgG produces).
Do not fettered by any theory or model of action, generally believe relevant to the second and third aspect of the present invention above-mentioned
Embodiment provides a kind of replacement scheme and/or improves therapeutic scheme, because endogenous immune component is (such as from resisting that immunity produces
Body and antigen-specific cellular) it is being complete administration of antigens binding site, and non-autologous anti-P2X7Antigen binding site
After cyclical level becomes to detect, it is provided that cell surface P2X7More extend and the higher exposure of receptor.It addition, it is general
All over thinking P2X7Receptor clustering (along with producing when providing the non-autologous of high concentration or exogenous antibodies in companion animals body) is minimum
Change the crucial P2X being attached to provide anticancer immunne response7The specific antibody level of epi-position, thus limit immunotherapy
Effect.The inventors discovered that, the immunity of companion animals, when the cyclical level of autoantibody generally detects, keeps away
Exempt from receptor clustering, and which improved effect of immunotherapy, when the cancer in this companion animals body can be particularly
When generally can not detect.
In an embodiment of the second and third aspect of the present invention, these choosings are not the most used for the animal for the treatment of
Antibody mediated immunity therapy or the therapy for treating of other forms.In another embodiment, these choosings come for treating according to said method
Animal be to have accepted or continued to accept antibody mediated immunity therapy for those for the treatment of of cancer.Antibody mediated immunity therapy is usual
It is directed to an animal needing treatment and uses (also referred to as " non-autologous ") antibody of external source, such as the adoptive transfer at antibody
In situation.Such as, this animal can accept any one of therapeutic antibodies, and these antibody have accepted relating to swelling
The registration examination & approval of the instruction of tumor.Avastin, herceptin, Mabthera are examples.Typically, this animal has received or just
Continuing a kind of anti-P2X of acceptance7Receptor antibody.Suitable anti-P2X7Antibody, they generation, manufacture, use and to one
The example used of companion animals is described in the embodiment relevant to a first aspect of the present invention.
It addition, these choosings can have when treatment for the animal that the second and third aspect according to the present invention is treated
Or may not have the cancer that can detect.When this animal does not have the cancer that can detect, it is easier to a kind of primary of detection or two
, because in the presence of cancer is with the amount that generally can not detect, there is considerably less available NOT function in level humoral response
Can property P2X7Receptor removes IgM or IgG from body fluid.
Can according to the type of the cancer that the second and third aspect of the present invention is treated and desired therapeutic outcome be as
Those described in the embodiment relevant to a first aspect of the present invention.
The purpose of the treatment of the second and third aspect according to the present invention is by P2X in animal body7The immunity of receptor
Induction or the formation of response at least minimize cancer progression.Therefore, choosing must be to produce foot for the animal for the treatment of
Enough immunne response meet this purpose.Generally this desired immunne response includes when this animal is by cancer, as in cancer
When recurrence excites, the ability of one or both of IgM and IgG producing circulation.
Can select by multiple method well known in the art or screen and describe the energy having and producing immunne response in this
The animal of power detects for immunodeficiency.Typically, choosing will have in normal parameters for the animal for the treatment of
The animal of at least one white cell component counting.Such as, the numeration of leukocyte being typically to have for the cat included in arrives 5.5
19.0×109Between/L, or lymphocyte count is 0.9 to 7.0 × 109Cat between/L.Neutrophil count can be
2 to 13 × 109Between/L;Monocyte count < 0.7 × 109/ L, eosinophilic granulocyte is less than about 1.1 × 109/ L and basophilic
Property granulocyte is less than about 0.1 × 109/L.Such as, be typically for the Canis familiaris L. included in the numeration of leukocyte that has 4.5 to 17.0 ×
109Between/L, or lymphocyte count is 0.9 to 3.5 × 109Canis familiaris L. between/L.Neutrophil count can arrive 3.5
12×109Between/L;Monocyte count < 1.2 × 109/ L, eosinophilic granulocyte is less than about 1.5 × 109/ L and basophilia
Granulocyte is less than about 0.1 × 109/L。
It will be appreciated that in certain embodiments, can fall for the cell counting of any one in these cellular blood components
Outside these scopes stated, this animal suffers from the situation of the leukemia of a kind of form, such as CML, CLL etc. the most wherein
Under.
A usual important factor is lymphocyte count and/or monocyte count.In more detail, to these groups
Point, when one or both of these countings are markedly inferior to the scope of statement, it is immunogenic that this animal can unlikely respond this
Use.
When this animal continues to accept antibody mediated immunity treatment, in an embodiment of the second and third aspect of the present invention,
The treatment of this antibody mediated immunity is allowed to be continued until desired clinical endpoint.Typically, this desired clinical endpoint is that cancer is reduced to
The level that generally can not detect.Then during immunization therapy or at the end of, evaluate this animal formed or produce right
P2X7The ability of the immunne response of receptor.Then when this evaluation discloses this animal may be from P2X7Immunogenic immunity is benefited
Time, then use this animal immune former.
In a preferred form of the second and third aspect of the present invention, in this animal body, it is produced from antibody mediated immunity
The level of the antigen binding site of the non-autologous or external source of the circulation of therapy, when this immunne response is formed in this animal body be
Generally can not detect.Importantly, a key of present inventor is the discovery that effect of Antybody therapy is at antibody combining site
Higher circulation composition time reduce, particularly when cancerous cell is in low-down copy number, or the most not
When can detect.This is considered as relative to the high concentration antigen binding site produced in standard antibody immunotherapy, thin in cancer
The non-functional P2X of the low copy number on born of the same parents7One function of receptor.Definitely, in example in this, present inventor has sent out
Existing, along with the cyclical level of antigenic specificity binding site increases, and cancer cell count reduces, by blocking the anti-of this receptor
The non-functional P2X of former specific binding antigen binding site7The probability of the gathering of receptor is the highest.This blocking-up increases
Add intended cytotoxicity, apoptosis or the probability of other effects combined by the antigenic specificity of antigen binding site,
This will be impossible.People can determine in circulation by detecting any standard serological techniques of the antibody in body fluid
The level of exogenous antigen binding site, a preferred example is the ELISA utilizing antibody to capture antigen binding site.
Outside upper, but being not desired to be assumed constraint, ladies and gentlemen inventor is it is considered that use immunity increasing in the presence of infusion antibody
Add this infusion antibody and can be incorporated into the risk in this immunogen, caused formation and the removing of immune complex, thus avoid
The induction of antigen presentation and antigen specific immune.Therefore, in certain embodiments, wait until to immunogenic anti-
Before the induction of former specific immune response, non-autologous or exogenous antigen binding site level is removed from circulation, is special
Useful.
Method in the second and third aspect of invention described herein needs at P2X to be used7Receptor (especially one
Non-functional P2X7Receptor) form immunne response in the animal body treated.Usually, immunogen is to non-functional for this purpose
Property P2X7Receptor rather than to functional P2X7Receptor draws the immunogen of immunne response.
The inventors discovered that, multi-epitope is present in large-scale species, it is meant that according to the present invention's in this
Second and third aspect, (i) antigen binding site or antibody can be cultivated in large-scale animal and treat for antibody infusion
And the animal of (ii) on a large scale species can treat by active immunotherapy.Following table demonstrates people's multi-epitope and at it
The % concordance of the epi-position in his species.
Table 2: people E200/E300 and the comparison of other species
This immunogen can include or consist of: includes a P2X7The peptide of the sequence of receptor.This peptide can comprise
At least one sequence, this sequence can exist on a MHC II quasi-molecule, or can be with a B
The immunoglobulin interaction that cell receptor or a B cell film combine.Typically, this peptide includes an inhuman source, excellent
Choosing is companion animals P2X7Receptor or a sequence of its fragment.
Known a series of peptide based immunogens and at PCT/AU2002/000061, PCT/AU2002/000061, PCT/
Discussing in AU2008/001364 and PCT/AU2009/000869, their content is combined in this in full with it.
The following describe including for non-functional P2X in those specifications7Receptor produces the table of immunne response
The exemplary peptides immunogen of position.
As discussed above, in one embodiment, this peptide based immunogens includes the P2X of part or all of dog or cat7It is subject to
Body sequence.
It will be appreciated that according to the second and third aspect of the present invention, these be only to formed immunne response useful can
Can immunogenic example.It addition, the present invention include as described in these applications to non-functional P2X7Receptor forms one
The purposes of other peptides that immunne response is useful.
Typically, this immunization protocol relates to 2 or more immunity.In the first immunity, this object of study may be right
Immunologic development IgM response.Second immunity may develop IgG response.Further immunity may increase this IgG response.
When this immunogen is a peptide, this peptide can be provided, preferably from about by the amount using about 0.1mg to 1mg every time
0.25mg to 0.75mg, preferably from about 0.5mg in a towser body, but halve in doggie or kitten body.
Another that can apply about 0.3mg peptide in a towser body is used as growth, but subtracts in doggie or cat body
Half.
In an embodiment of the second and third aspect of the present invention, it is being applied for antibody mediated immunity therapy
When the cyclical level of antigen binding site generally can not detect, carry out the first immunity.In other words, to associated cancer biomarker
The circulating antibody of thing can not be detected in peripheral blood.Then the level produced at ensuing a few week monitoring IgM.First
In about 4 to 5 week after immunity, the level of IgM antibody may have already decreased to insignificant cyclical level.Carry out second the most at this moment
Immunity, and the level produced at ensuing a few week detection IgG.In ensuing some months/year, immunity can be carried out
Further test, and the immunity of increase can be provided as required.
As discussed above, this immunne response can with one biomarker of targeting, this biomarker with led to
The biomarker crossing antibody mediated immunity therapy targeting is different.Such as, anti-CD 20 antibodies may be used for antibody mediated immunity therapy, and one
Individual non-functional P2X7Immunogen is for producing an immunne response.
In another embodiment of the second and third aspect of the present invention, by antibody mediated immunity therapy and immunity one list of targeting
Only biomarker.Such as, one is pointed to P2X7The monoclonal antibody of the epi-position (such as E300 epi-position) on receptor can
For antibody mediated immunity therapy, and it is used for forming targeting P2X7On the immunne response of different epi-position (such as E200 epi-position)
Immunogen may be used for immunity.
One peptide based immunogens of the second and third aspect for the present invention in this can have 6,7,8,9,10,11,
12, the length of 13,14,15,16,17,18,19,20,21,22,23,24,25 or 26 residues.
In an embodiment of the second and third aspect of the present invention, according to a method of the present invention, it is used for being formed
The immunogen of immunne response is to have P2X7The peptide of the sequence of receptor, this P2X7Receptor can have or can not have cis
(cis) Pro210 of conformation.
This immunogen can be P2X7Extracellular domain or P2X7Any one of isotype or multiple form.Should
Immunogen can by soluble form or with solid phase (such as cell membrane, beadlet or other surfaces) associate and provide be used for using.
There is disclosed herein for screening be used as immunity originally formed immunity according to the method for the present invention in this
The method of the peptide of response.One example includes erythrocyte purposes in rosette test.In this experiment, it is attached to function
An antibody on property receptor is used as a positive control, observes rosette wherein.If Flos Rosae Rugosae can not be formed
Knot, it is determined that this test antibody not can be incorporated on functional receptor.If it is observed that it is attached to one expresses non-functional
In the cell line of receptor (include discussed herein those), it is determined that it is attached on non-functional receptor.
Peptide in the present invention can be made by this area any number of known technology, these technology include solid phase synthesis and
Recombinant DNA technology.
As known in the art, carrier is to can be incorporated into peptide epitopes thus to strengthen immunogenic material.One
A little carriers, by being attached on multiple peptide, thus provide the molecule with increase to the host that will develop immunne response wherein
One antigen of amount, accomplishes this point.
Preferably carrier includes bacteriotoxin or toxoid.Other suitable carriers include Neisseria meningitidis adventitia egg
In vain, albumin (such as bovine serum albumin), synthetic peptide, heat shock protein, KLH, B. pertussis proteins, from hemophilus influenza
Protein D and from the toxin A of Clestridium difficile, B or C.
When this carrier is bacteriotoxin or toxoid, diphtheria toxoid or tetanus toxoid are preferred.
Preferably, this carrier comprises can be with the functional group of the reactive polypeptide of the present invention, or can be modified to can be with
This reactive polypeptide.
This immunogen can subcutaneous, Intradermal and/or intramuscular administration.
In a preferred form, for a P2X7Receptor forms an immunne response and sends out for described here
The compositions of bright method includes adjuvant or compound, is used for strengthening immunne response.
Known a lot of adjuvant;See also Allison (Ai Lisen), (1998, Dev.Biol.Stand. (grow biology
Standard), 92:3-11) (being incorporated herein by reference), Unkeless (Ang Keliesi) et al. (1998,
Annu.Rev.Immunol. (immunology annual review), 6:251-281) and Phillips (Karen Phillips) et al. (1992,
Vaccine (vaccine), 10:151-158).Can according to invention utilize Exemplary Adjuvants include, but are not limited to cell because of
Son, aluminium salt (such as aluminium hydroxide, aluminum phosphate etc.;Baylor (Beile) et al. (Vaccine (vaccine), 20:S18,2002)), solidifying
Glue-type adjuvant (such as calcium phosphate etc.);Antimicrobial adjuvant (such as includes the immunomodulating DNA sequence of CpG motif;Endotoxin is such as
Monophosphoryl lipid A, Ribi (Lay ratio) et al. (1986, Immunology and Immunopharmacology of
Bacterial endotoxins (immunology of bacterial endotoxin and immunopharmacology), Plenum Publ.Corp. (Pu Lainan
Publishing company), NY, p407,1986);Extracellular toxin such as cholera toxin, HLT and pertussis toxin, PT,
Muramyldipeptide, etc.);([(Novartis is public for Novartis for such as Freund adjuvant, MF59 for oil emulsion and adjuvant based on emulsifying agent
Department)], SAF, etc.);Particulate adjuvants (such as liposome, biodegradable microspheres, etc.);Synthetic adjuvant (the most non-ionic block
Copolymer, muramyl peptide analog, polyphosphazene, synthesis polynucleotide, etc.);And combinations thereof.Other Exemplary Adjuvants
Including some polymer (such as group of polyphosphazenes;Be described in United States Patent (USP) 5,500,161), Q57, saponin (such as QS21,
Ghochikyan (Gu Jikeyang) et al., (vaccine (vaccine)), 24:2275,2006), zamene, tetrachloro ten oxide
(tetrachlorodecaoxide), CPG7909 (Cooper (cooper) et al., (vaccine (vaccine)), 22:3136,
2004), poly-[two (carboxyphenoxy) phosphonitrile] (PCCP;Payne (Penn) et al., (Vaccine (vaccine)), 16:92,
1998), interferon-γ (Cao (Cao) et al., (Vaccine (vaccine)), 10:238,1992), block copolymer P1205
(CRL1005;Katz (card hereby) et al. (Vaccine (vaccine)), 18:2177,2000), interleukin II (IL-2;Mbwuike
(Wei Ke) et al. (Vaccine (vaccine)), 8:347,1990), polymethyl methacrylate (PMMA;Kreuter (Crewe pool) etc.
People, (J.Pharm.ScL (Pharmaceutical Sciences magazine)), 70:367,1981), etc..
In an embodiment of the second and third aspect of the present invention, at one according to describing the one of the present invention in this
Individual method, provides on a phage surface for the immunity of an animal and comprises a P2X7The peptide immunity of receptor sequence
Former.
Still at other aspect, the invention provides a kind of test kit or the compositions cancer in companion animals body and control
Treating, this test kit includes:
One whole antibody including a variable domains, or one fragment;Or
One P2X7Receptor, or a P2X7One fragment of receptor;
Written explanation in a method described here.
Preferably, this antibody or fragment are attached to a P2X7Receptor, it is therefore preferable to a non-functional P2X7Receptor.More
Preferably, this antibody or fragment are not joined to functional P2X7On receptor.
Preferably, this written explanation with the form of a label or packaging with operation instruction for describing in this one
In individual method.
Example
Example 1 cat 1 (GB)
Wide SCC (squamous cell carcinoma) scalp and lip, area is up to 4cm2And account for the full depth of lip.Controlling
Before treatment, the left lip of SCC has diffused into subcutaneous angle of mandible.Before the treatment, IHC (SABC) is caught for nf-at the left lip of SCC
P2X7Target recipient.
The partial efficacy injected with (i.t.) in tumor
As IHC discloses, target recipient is widely distributed in infected tissue
With dosage 3mg/kg, use under fluid maintains speed, single infusion targeting nf-P2X7The cancer of receptor is special
Property treatment antibody
By the 4th day, have what tumor removed to understand sign
By the 14th day, after 3mg/kg single dose IV (intravenous injection), after treating 2 weeks, the left labial tumor of most SCC
It is eliminated.After 3mg/kg IV, after treating 2 weeks, SCC bunch above left eye also removes.Now, at original disease site
Epithelium gross weight changes substantially
After 3 IV, scalp SCC and lip SCC is substantial amounts of is removed, despite the new epithelium by sick cat scratcs within 5 weeks
The sign of tissue.Center SCC pathological changes that be positioned at lower jaw center line, that penetrate in skeleton has white nodositas scar tissue now
Outward appearance.Unlike the patient's condition wherein having obvious severe pain when treatment starts, this disease cat is not the pathological changes position with process
Point institute is worried.
After the IV treatment of 6 months, this patient's condition solves, and wherein discloses via the X-ray in interior mandibular bone, even has new
Skeleton increases
Elapse over time, lose effect due to the appearance of anti-sheep antibody, total accumulation of the clinical clearance rate of impact
Dosage is estimated as 30mg/kg to 40mg/kg
Example 2 cat 2 (AL)
Before i.t. injects, nose has SCC
Only 1x i.t. injects, because cat 21 years old, owing to general anesthesia causes cortical blindness to continue some hours
Subsequently with the anti-nf-P2X in local7IgG
Within 5 days ,-SCC nose forms new organization
Within 19 days ,-SCC nose forms more new organization
Example 3 cat 3 (PC)
Cancer of pancreas is with to liver and mesenteric mesaraic transfer
After 2 weeks intravenous (i.V.) infusions, ultrasonic scanning display 1cm level mesentery transfer is inconspicuous
After 2 weekly intravenous injections, by the sign of some tumor lysis (liquid) of ultrasonic scanning
After 4 weeks, Secondary cases liver is retracted to 2cm from diameter 5cm
After 4 weeks, the constitutional pancreas of 5-6cm diameter has the 80% of about its liquefaction quality
Behind 5th week end, due to pancreas tumor dissolve/hemorrhage to abdominal part and possessory requirement, carried out peaceful and comfortable
Extremely
Example 4 cat 4 (FH)
Nose SCC expands to the bridge of the nose from left nose hole 2cm
At the end of 2008 after operative treatment, biopsy discloses the SCC recurred widely
After 5mg/kg single intravenous dose, upper nose surface tumours volume reduces, and the sponge concordance on this surface becomes
Obtain firm
After the most weekly infusion, this pathological changes is the most obvious.Application third time infusion, and at 2 weeks ends,
The clinical indication of all of pathological changes does not exists.Other infusion is applied to guarantee the residue preneoplastic cell that may have existed
Elimination.
Under accumulated dose 18mg/kg, clinical removing in 21 days
No longer recur after 14 months, so sick cat looks as curing completely
Example 5 cat 5 (CO)
Medical history
Sick cat in 2008 from removing Bao Wen sample (Bowen ' s-like) pathological changes from Zuo Nie district.In March, 2009 once
Inspection being noticed, this pathological changes has reproduced and occurred a new pathological changes in opposition side.These are the living tissues with following result
Check:
Diagnosis
Have by the time the most serious hemocyte crust, epidermis scar and moderate Perivascular eosnophilia dermatitis how in
Heart squamous cell carcinoma in situ.Skin biopsy from left ear.
All and interstitial the eosnophilia dermatitis of moderate proliferating vessels is with moderate epidermal Fiber Laminated hamartoplasia.Come
From the biopsy of cervical region.
Along with moderate hyperpigmentation, moderate erythrocyte crust and the wide skin scar in more major part cranium
Multicenter squamous cell carcinoma in situ.Biopsy from auris dextra.
Notes and commentary
This cat has multiple stove points of the neoplastic transformation of epidermis and hair follicle tissue, with multicenter squamous cell carcinoma in situ or
Bao Wen sample is sick consistent.These pathological changes are similar with the biopsy that in June, 2008 submits to.In the part checked, there is no squamous
The sign of epithelium infiltrating carcinoma.
SCC (Bao Wen Shi (Bowen ' s) in situ)
To the infusion anti-nf-P2X of 5mg/kg sheep7IgG does not has untoward reaction
After 2 weeks, pathological changes has significantly reduced but still wide, due to initial improvement, so application of second time infusion
After veterinary dermatologist studies, all wide Bao Wen sample pathological changes are eliminated, and this veterinary dermatologist notes
Meaning is to after lesion surface and infections relating are eliminated, and the deep SCC at auris dextra ditch is only apparent property.Disease must be avoided
Cat plugs and tears new epithelium, limits necklace by additional one and allows skin surface to heal.
Example 6 Canis familiaris L. 1 (CJ)
In 30kg Canis familiaris L., the abdominal part at veutro has angiosarcoma medical history.Because tumor so has aggressiveness, after Repeated Operation,
This Canis familiaris L. is no longer surgical candidates.Use intratumor injection nfP2X7IgG and 3 IV infusion nfP2X7The antibody of affinity purification is controlled
Treat.Intratumor injection 6mg antibody, in the dermatosis of 6cm diameter, illustrated the reduction of 80% in one week, along with the most swollen
Oncolysis is as obvious secretions.
Carry out 1 intratumor injection under dosage by 2-3.4mg/kg administration and 3 intravenous injections treat 4 weeks
With the anti-nf-P2X of sheep7After IgG treatment, gross tumor volume reduces
Due to tumor lysis/seepage symptom and the possessory requirement of these big tumors (gross weight 1-2kg),
On March 21st, 2010 practises mercy killing
Example 7 Canis familiaris L. 2 (MO)
In neuropathology, it is found to be transitivity mesothelioma with the transitional cell carcinoma (TCC) of malignant ascite
By carrying out 3 intravenous medical treatment under the dosage of 1-2.7mg/kg together with chemotherapy 2 weeks
At second week, tumor reduces 15%, although there is also ascites
At the 3rd week, under possessory requirement and oppose the suggestion of veterinary, stop treatment
Example 8 Canis familiaris L. 3 (PI)
Lymphadenomatous special treatment and rehabilitative training-the outward appearance of mastocyte between two fingers in the middle of before right pawl
Ledge under hard and foot pad causes discomfort.Operation may require that removal foreleg is to maintain the limit of 3cm
After mastocyte lymphoma special treatment and rehabilitative training-IV5mg/kg1 week-volume reduction 40%
The week present deliquescing of pathological changes of mastocyte lymphoma special treatment and rehabilitative training-2 and volume are greatly reduced,
There is no prominent part under foot pad, and in Canis familiaris L. body, there is no the sign of discomfort.The entity core of pathological changes is limited to list now
Individual finger, the reacting cells capsule along with surrounding is sufficiently flexible.
Metastasis in subscapular lymph nodes can not detect by the 2nd week
Primary affection 3 months major parts in appearance keep constant
Owing to primary affection becomes to fester under claw, under possessory requirement, Canis familiaris L. is practised mercy killing
Postmortem biopsy illustrate disease Canis familiaris L. without all tumors, this primary affection site does not has mastocyte, comprises anti-
Answering property lymphocyte
Pathological changes may be removed by the accumulated dose less than 30mg/kg
Example 9 Canis familiaris L. 4 (BE)
After extreme pain and cyllopodia occurs in sick Canis familiaris L., upper left humerus is diagnosed to be osteosarcoma via CT scan, prepares to carry out
Euthanasia.
Start by the weekly infusion of 10mg/kg.In one week, sick Canis familiaris L. and the owner again together with movable, and
Seem substantially not have misery, and want to go for a trot.
At the 9th week, obtaining diagnosis tissue after CT scan and treatment under general anesthesia, this time is considered as bone
Bone regrows the shortest time that easily can detect
At the 9th week, biopsy there is no the sign of tumor cell, seem the best with seasonal disease Canis familiaris L.
Sick Canis familiaris L. is owing at left humerus fractured near end, being carried out euthanasia at 5th month.The biopsy of disease site
It is shown without remaining osteosarcoma sign.Seem there is obvious overall relief, but bone is because tumor is the thinnest and crisp.
In this case, it should the outside clamping plate of application protect bone to carry out associated treatment to assist bone weight simultaneously
Raw.
Example 10 Canis familiaris L. 5 (WC)
There is the transitivity mastocyte lymphoma (2 grades) of high di (25).On rib, shoulder and back leg have many
Place pathological changes > 5cm.Carry out the weekly IV infusion of 10mg/kg immediately.
At first week end, total lesion volume reduced 75%, as PI illustrates, consistent with the expectation quickly removed.
Major lesions still has long-pending block, but after second time infusion, reduces further at second week end
After three infusions and one week draw a response, at the 3rd week end on schedule by ultrasonic complete with cytology
Surface analysis disease site
Carry out after the last pin of all disease site is pumped in 3 months and when 6 months.There is no the mark of any mastocyte
As.
Within 13 months, seasonal disease Canis familiaris L. is not deemed tumor.
Example 11 Canis familiaris L. 6 (HL)
Sick Canis familiaris L. presents the high-level transitivity mast cell tumor being derived from lower limb with lymphatic metastasis.
Infusion of therapeutic is passed through 6 weeks once in a week under the dosage of 10mg/kg.
Eliminate to all of swelling in the 3rd week
At the 6th week, pathology are shown at tumor sites did not had mastocyte
Sick Canis familiaris L. is not recurrence in 1 year
Example 12 antibody manufacture
In phosphate buffered saline (PBS) (PBS), by the 500 μ anti-P2X of g sheep of conjugate7Antibody (the P2X of about 100 μ g7, table
Position) it is diluted to 0.8mL, and with 1.2mL Freund's complete adjuvant (Freund ' s Complete adjuvant) emulsifying.With anti-
Former/adjuvant Emulsion carries out both subcutaneous injection and intramuscular injection in multiple site to sheep.After eight weeks, these sheep phases
Commensurability injects in multiple sites again with the conjugate of Freund's complete adjuvant emulsifying.Repeat this process after 4 weeks, and these move
Thing is from taking blood from jugular vein.The serologic test antibody specificity collected.Then these sheep at the interval regular injection of eight weeks and take
Blood provides a serum pond comprising specific antibody.
Other sheep is injected with the conjugated antigen of same dose with being similar to above scheme, but uses different adjuvant.
In these animal bodies, the Quill A/DEAE dextran solution of the antibody of the dilution of 0.7mL and 0.1mL is (in the PBS of every mL
The Quill A+25mg deae dextran of 2.5mg) and 1.2mL ISA50V Montanide mixing.At multiple site skins
Hemostasis and intramuscular injection Emulsion.The antibody using this adjuvant to produce creates the same with those produced with Freund adjuvant
Specificity.
Use the two kind adjuvants identical with in sheep and identical infusion protocol to cultivate antibody in rabbit, only difference is that
The conjugate of 300 μ g amounts is used for injection.The antibody cultivated has phase homospecificity with those produce in sheep, and can
The epi-position resisted with they readily distinguishing cultivation.
In mice, cultivate antibody resist those epi-positions combined, and also anti-non-functional P2X7The uncombined table of epi-position
Position (it can distinguish those receptors that can not form (from) hole and therefore can not apoptosis).In these experiments, use
Adjuvant is product I mmunEasy of Qiagen GmbH (QIAGEN Pty Ltd), and it comprises immuno-stimulatory products CpG DNA
(trade mark of Ke Lai pharmacy group (Coley Pharmaceutical Group Inc.)).At 60 μ L PBS and 25 μ L
ImmunEasy adjuvant dilutes the epi-position of 62.5 μ g or the epi-position/mice of combination.In multiple sites, subcutaneous injection and intramuscular note
Penetrate mice.Repeat the program after two weeks and again repeated after another two weeks.The blood of mice is taken after third time is injected 8 days.With
The antibody that this method is cultivated in mice also is able to distinguish different P2X7, epi-position, and anti-P2X7Resisting of non-functional epi-position
Body and those antibody cultivated in sheep and in rabbit provide result.
The induction of example 13-immunne response in companion animals body
Materials and methods
Peptide
The peptide based immunogens of GHNYTTRNILPGLNITC (SEQ No. ID: the 3) form of synthesis of high purity, residual at C-terminal Cys
Ji Chu is added thereto to cross-linking agent maleimidocaproyl-N-hydroxy-succinamide (MCS).This peptide is linked to one
Carrier protein keyhole limpet hemocyanin (KLH) so that peptide is 40% to the average percentage of total peptide-protein conjugates.This peptide or
The similar replacement peptide GHNYTTRNILPGAGAKYYKENNVEKC being attached to KLH has respectively constituted primary and compound selectivity
Epi-position target, they make the nfP2X that will prepare from natural receptor7Receptor can break up.
Adjuvant
Using Imject Alum, one is generally used in people's immunity, a kind of algeldrate gold and magnesium hydroxide add
The adjuvant of the approval of the liquid formulations composition of the inert stable agent in a upper gel.At 2.5mg/mL conjugate (1mg/mL
Peptide) drip this peptide-protein conjugates, wherein 0.75mL to be comprised equal to 0.5mL conjugate the target peptide table of 0.5mg under concentration
The amount of the adjuvant of position is sufficiently mixed in adjuvant.
Immunity
Immunization protocol consists of: primary inoculation (twice subcutaneous injection and twice intramuscular of an accumulated dose 0.5mg peptide
Injection), after the later moon, apply accelerator with same way 0.3mg peptide.Collect immediately with after injecting one week before the injection
Blood serum sample.It is desirable that at anti-nfP2X7The last infusion of antibody uses inoculation after being not less than one month, by remaining specificity
Anti-nfP2X7Antibody infusion guarantees do not have immunogenic isolation.
ELISA
The anti-nfP2X of specificity is measured by ELISA7Antibody response.Briefly, this elisa plate is coated with specific target peptide
Epi-position, adds patients serum with the concentration successively decreased thereon.After cleaning, apply suitable two grades of anti-human antibody (anti-IgM or anti-igg
Type) the specific human anti-nfP2X that with IgM or IgG form exist is detected and determined in patients serum7The concentration of antibody.
After inoculation, do not have IgG to detect, but IgM in a small amount detected.Along with this growth, IgM concentration has returned to base
Line zero, and IgG produces with the concentration higher than initial IgM, if there is not nfP2X in existing tumor7Receptor sinks (sink).
In its primary tumo(u)r by anti-nfP2X7In the animal patient that immunotherapy is removed, in the case of there is no this sinking, inspection
Measure in serum, have the anti-nfP2X of specialized endogenous7The obvious group of antibody, rank is 25mg/kg.
Fig. 3 shows the ELISA result of a sick dog, this immunity proceeded as above.Specificity circulating antibody freely
The recurrence of level and initial clearance rate the most completely and shortage transitivity mast cell tumor be consistent.
It will be appreciated that the present invention disclosing in this manual and defining expand to mentioned or from context or
All alternative combinations of two or more independent features obvious in accompanying drawing.All these different combinations constitute the present invention
Different alternative aspect.
Claims (6)
1. it is used for being attached to a kind of Canis familiaris L. non-functional P2X7Whole antibody on receptor or its comprise a sheet of a variable domains
Section preparing a kind of purposes in treating Canis familiaris L. body in the medicine of cancer or the patient's condition being associated with cancer or symptom, wherein this
Planting cancer is mastocytoma.
2. purposes as claimed in claim 1, wherein this antibody or its fragment are not joined to functional P2X7On receptor.
3. purposes as claimed in claim 1, wherein this antibody or its fragment are from a kind of polyclonal antiserum.
4. purposes as claimed in claim 1, wherein this antibody or its fragment are cultivated, this antigen pair for a kind of antigen
It is xenogenesis for it carries out the immune system cultivated wherein.
5. purposes as claimed in claim 4, wherein this antigen is xenogenesis for Canis familiaris L..
6. purposes as claimed in claim 1, wherein this antibody or its fragment are xenogenesis for Canis familiaris L..
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610703907.3A CN106310245A (en) | 2010-09-10 | 2011-09-09 | Companion animal treatments |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010904080 | 2010-09-10 | ||
AU2010904080A AU2010904080A0 (en) | 2010-09-10 | Companion animal treatments | |
AU2011902626 | 2011-07-01 | ||
AU2011902626A AU2011902626A0 (en) | 2011-07-01 | Companion animal treatments II | |
PCT/AU2011/001166 WO2012031333A1 (en) | 2010-09-10 | 2011-09-09 | Companion animal treatments |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610703907.3A Division CN106310245A (en) | 2010-09-10 | 2011-09-09 | Companion animal treatments |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103298487A CN103298487A (en) | 2013-09-11 |
CN103298487B true CN103298487B (en) | 2016-12-14 |
Family
ID=
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1625565A (en) * | 2001-09-03 | 2005-06-08 | 因特里特有限公司 | Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions |
CN102762595A (en) * | 2009-12-24 | 2012-10-31 | 生物权威国际有限公司 | Antibodies to non-functional oligomeric p2x7 receptors |
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1625565A (en) * | 2001-09-03 | 2005-06-08 | 因特里特有限公司 | Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions |
CN102762595A (en) * | 2009-12-24 | 2012-10-31 | 生物权威国际有限公司 | Antibodies to non-functional oligomeric p2x7 receptors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106310245A (en) | Companion animal treatments | |
CN103702683B (en) | Therapeutic alliance | |
KR102595561B1 (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
ES2782834T3 (en) | Use of semaphorin-4D inhibitory molecules in combination with immunomodulatory therapy to inhibit tumor growth and metastasis | |
KR20180128496A (en) | Cancer immunotherapy by immune activation or immunomodulation through glycosylated antigen | |
CN110536905A (en) | Anti-PD-1 Antibodies for the Treatment of Lung Cancer | |
KR20160137984A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
US20170106067A1 (en) | Combinatorial immunotherapy for pancreatic cancer treatment | |
JPH11509558A (en) | Method and composition for reconstituting an antigen containing multiple epitopes to elicit an immune response | |
Caballero et al. | Safety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: a dose-escalation phase I study trial | |
US11040223B2 (en) | Compositions and methods related to xCT peptides | |
CN103298487B (en) | Companion animals is treated | |
Wagner et al. | Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine | |
KR20230031015A (en) | Antibody pharmaceuticals for preventing or treating autoimmune disease | |
JP2021014460A (en) | Pain treatment | |
CN102281867A (en) | Composition for targeting dendritic cells | |
AU2014296038A1 (en) | Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens | |
CN115956088A (en) | Anti-tumor combination therapy comprising an anti-CD 19 antibody and a polypeptide that blocks a SIRPa-CD 47 innate immune checkpoint | |
JP2007320969A (en) | Method for reconstructing multiple epitope-containing antigen for causing immune response, and composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: New South Wales, Australia Applicant after: Bio authority (Australia) limited liability company Address before: New South Wales, Australia Applicant before: Biosceptre International Limited |
|
GR01 | Patent grant |